Amide Compounds Broad-Spectrum Antiviral Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral drugs are often toxic, insufficiently effective, and have a limited spectrum of activity, leading to rapid emergence of resistant virus variants, and there is a lack of effective treatments for RNA- and DNA-containing viruses such as adenoviruses, herpesviruses, enteroviruses, and respiratory syncytial virus.
Innovation Solution
Development of specific amide compounds or their pharmaceutically acceptable salts that can be used as non-toxic antiviral agents effective against a broad range of RNA- and DNA-containing viruses, including those belonging to the Enterovirus, Metapneumovirus, Pneumovirus, and Coronaviridae families, administered in solid dosage forms or as part of pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antiviral drugs are used, then viral infections can be treated, but the drugs are often toxic to humans and insufficiently effective
Solution Approach 1:
The patent modifies the chemical structure of known antiviral compounds by changing parameters such as substituting hydrogen atoms with fluorine, chlorine, or other groups, and modifying the core molecular scaffold. These parameter changes in the chemical structure aim to improve therapeutic effectiveness while reducing toxicity to humans.
Solution Approach 2:
The invention creates composite molecular structures by combining different functional groups and molecular fragments in specific arrangements. These composite amide compounds integrate hydrophobic and hydrophilic regions, aromatic and aliphatic components, to optimize both antiviral activity and safety profile.
2Adaptability or versatility
If existing antiviral drugs are used, then some viral infections can be treated, but they have a limited spectrum of activity and promote rapid emergence of resistant virus variants
Solution Approach 1:
The patent designs amide compounds with a core structure that can interact with conserved regions of multiple virus types including RNA viruses and DNA viruses. The molecular architecture incorporates features that allow binding to different viral targets, providing broad-spectrum activity against influenza, herpes, HIV, and other viruses while reducing the likelihood of resistance development.
Solution Approach 2:
The antiviral compound is divided into distinct functional segments including a hydrophobic region, a hydrophilic region, and specific binding moieties. This segmentation allows different parts of the molecule to interact with different aspects of the viral lifecycle or different viral targets simultaneously, enhancing versatility and reducing resistance.
3Adaptability or versatility
If specific amide compounds are developed for broad antiviral activity, then spectrum of activity is improved, but drug development complexity increases
Solution Approach 1:
The patent employs systematic parameter changes in the molecular structure, such as varying substituents at specific positions on the core amide structure. This structured approach to modifying chemical parameters allows for methodical optimization of broad-spectrum activity while maintaining a manageable development framework based on known pharmacophores.
Data Source
AI summary
The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.